Current international guidelines recommend analysis of the following seven genes before starting palliative intent therapy for lung adenocarcinoma: KRAS, EGFR, ALK, ROS1, HER2, BRAF, RET [130]. This evidence concerns the gene ERBB2 and lung adenocarcinoma.